YOLFTbeta
68

Jiangsu Aidea Pharmaceutical Co Ltd

688488 · SHG · Healthcare / Biotechnology

11.59CNY-0.57 (-4.69%)

Price History

Full chart

Market Stats

Previous Close12.16
Open12.17
Day Range11.56 – 12.21
52-Week Range11.40 – 22.55
Volume7.70M
Market Cap7.00B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.02
Dividend Yield0.00%
Beta0.49
50-Day Avg15.87
200-Day Avg16.21

About

Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products. The company was formerly known as Jiangsu Aidea Pharmaceutical Co., Ltd. and changed its name to Jiangsu Aidea Pharmaceutical Group Co., Ltd. in July 2025. Jiangsu Aidea Pharmaceutical Group Co., Ltd. was founded in 2009 and is headquartered in Yangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jie Zhang
  • Employees760
  • HeadquartersNo. 69, Xinganquan West Road, Yangzhou, China, 225008, China
  • Websitehttps://www.aidea.com.cn

Leadership

  • Mr. Jie ZhangCEO, President & Director · b. 1970
  • Ms. Yan LiuFinancial Director, Board Secretary, Accounting Supervisor & Director · b. 1982
  • Ms. Guang Rong WangVP & Director · b. 1977
  • Mr. Gaohong GuSenior Vice President · b. 1967
  • Mr. Tie SunHead of Biopharmaceutical R&D · b. 1978
  • Mr. Hong QinVice President · b. 1981
  • Mr. Qide LiDirector of Pharmaceutical Research Institute · b. 1980
  • Mr. Yu YuanQuality Center Director · b. 1979
  • Mr. Gufang SuDeputy Director of Process R&D · b. 1973

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue257.84M136.26M276.91M345.23M289.06M255.71M244.22M411.36M417.80M720.67M
Growth (%)--47.15%+103.21%+24.67%-16.27%-11.54%-4.49%+68.44%+1.57%+72.49%
Cost of Revenue136.06M96.49M167.87M199.07M145.22M181.33M172.18M245.01M224.53M238.82M
Gross Profit121.78M39.77M109.03M146.15M143.84M74.38M72.04M166.36M193.28M720.67M
Gross Margin47.23%29.19%39.38%42.34%49.76%29.09%29.50%40.44%46.26%100.00%
Operating Expense103.93M84.46M100.81M110.95M94.29M118.22M214.11M258.41M357.74M672.92M
Operating Income17.85M-44.68M8.22M35.20M49.55M-43.84M-142.07M-92.05M-164.47M47.75M
Operating Margin6.92%-32.79%2.97%10.20%17.14%-17.14%-58.17%-22.38%-39.36%6.63%
EBITDA34.73M-28.04M29.34M64.73M71.82M-14.69M-105.12M-38.39M-103.06M71.76M
EBITDA Margin13.47%-20.58%10.60%18.75%24.85%-5.74%-43.04%-9.33%-24.67%9.96%
Net Income14.24M-37.99M8.62M33.65M39.77M-29.99M-124.09M-76.07M-141.20M-19.73M
Net Income Margin5.52%-27.88%3.11%9.75%13.76%-11.73%-50.81%-18.49%-33.80%-2.74%
R&D18.93M37.71M37.77M27.86M26.32M47.67M63.91M63.18M103.33M87.37M
R&D as % of Total Revenue7.34%27.67%13.64%8.07%9.10%18.64%26.17%15.36%24.73%12.12%
Interest Expense1.56M1.05M1.89M4.94M3.01M335.19K4.01M11.76M15.49M15.62M
Interest Expense % of Total Revenue0.60%0.77%0.68%1.43%1.04%0.13%1.64%2.86%3.71%2.17%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets443.55M659.24M708.95M780.98M1.45B1.43B1.66B1.75B1.87B1.91B
Total Liabilities143.16M145.14M186.24M224.74M86.97M124.82M456.23M621.03M802.48M839.37M
Total Equity300.40M514.09M522.71M556.24M1.36B1.31B1.20B1.13B980.89M964.68M
Cash32.28M158.50M81.40M129.69M244.68M442.71M134.91M225.36M335.34M371.16M
Total Debt40.00M60.00M101.00M132.19M15.66M5.59M208.77M412.30M314.76M-
Net Debt7.72M-98.50M19.60M2.49M-229.02M-437.11M73.86M103.09M-20.58M65.75M

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow31.29M-67.18M-33.50M56.20M56.17M-12.37M-92.55M-166.22M-37.50M17.63M
Investing Cash Flow-22.34M-56.45M-82.50M-37.01M-574.45M230.53M-405.72M73.44M85.10M-
Financing Cash Flow6.05M252.90M37.80M23.45M626.70M-22.92M196.03M190.78M54.86M-
Capital Expenditure71.01M85.79M89.50M33.50M42.43M94.78M140.30M71.20M44.56M47.93M
Free Cash Flow-39.72M-152.97M-123.00M22.70M13.74M-107.15M-232.85M-237.43M-82.06M-30.30M
Dividends Paid12.80M1.05M3.20M5.60M3.12M20.16M3.47M11.66M15.85M20.87M
FCF to OCF-126.96%227.70%367.17%40.39%24.46%866.14%251.58%142.83%218.84%-171.87%
Dividend Paid to FCF-32.23%-0.69%-2.60%24.67%22.74%-18.81%-1.49%-4.91%-19.32%-68.87%

Earnings

Report DateSep 30, 2020Dec 31, 2020Apr 28, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----------
EPS Actual0.010.020.030.00-0.01-0.09-0.05-0.11-0.02-0.110.00
Surprise-----------
Timing-----------

Key Statistics & Ratios

Market Cap7.00B
Enterprise Value7.29B
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.68
Price / Book7.68
EPS-0.02
Book Value2.17
Revenue (TTM)722.54M
Gross Profit (TTM)467.97M
EBITDA104.40M
Profit Margin-0.80%
Operating Margin10.90%
Return on Equity1.34%
Return on Assets1.65%
Shares Outstanding420.78M
Shares Float207.37M
Beta0.49
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20211×
0.05Jun 24, 2021